Poland· PL-100461434
Xerava
A eravacycline product containing eravacyclinum, registered in Poland by PAION Pharma GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Eravacycline is registered in 11 of 19 countries.
Countries holding a registration under ATC J01AA13 (eravacycline), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Eravacycline · ATC J01AA13
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Eravacyclinum
- Manufacturer
- PAION Pharma GmbH
- Country
- Poland (PL)
- ATC code
- J01AA13
- ATC class
- Eravacycline
- Defined daily dose
- 0.14 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04260727580322
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
31 interactions on record for eravacycline.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eravacycline · interactions on record
31 records
- 11 severe
- 11 moderate
- 9 minor
Most severe, free to view
- AcitretinD05BB02severe
- IsotretinoinD10AD04severe
- IsotretinoinD10BA01severe
- Aminolevulinic acidL01XD04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Eravacycline in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXERAVAPAION Pharma GmbH, Aachen
- SpainXERAVA 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPaion Pharma Gmbh
- FinlandXeravaPAION Pharma GmbH
- United KingdomXerava 100mg powder for concentrate for solution for infusion vialsPAION Pharma GmbH
- IrelandXerava 100 mg Powder for concentrate for solution for infusionPaion Pharma GmbH
- IcelandXeravaPAION Pharma GmbH
- BelgiumXerava 100 mgPaion Pharma
- SwedenXerava 100 mg Pulver till koncentrat till infusionsvätska, lösningPAION Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xerava
- Liechtenstein · Xerava
- Norway · Xerava
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2b99194c-b314-4932-bbe6-bc4563d6dae3 GET /v1/drugs/2b99194c-b314-4932-bbe6-bc4563d6dae3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "100 mg",
"packaging": "Rp ¦ EU/1/18/1312/004 ¦ 142779\n12 fiol. 100 mg proszku\nRp ¦ EU/1/18/1312/003 ¦ 142780\n1 fiol. 100 mg proszku\n04260727580322 ¦ Rp ¦ EU/1/18/1312/005 ¦ 142781\n10 fiol. 100 mg proszku",
"substance": "Eravacyclinum 100 mg",
"common_name": "Eravacyclinum",
"pl_product_id": "100461434",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about eravacycline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.